{'fraction_non_alphanumeric': 0.0259222333000997, 'fraction_numerical': 0.018943170488534396, 'mean_word_length': 6.120567375886525, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: Complete remission followed by lethal sepsis

Posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of malignancies that occur in approximately 3% of adult liver transplant recipients. The prognosis is poor with reported 5and 20year survival rates of 69% and 45%, respectively. Although no generally accepted guidelines for the treatment of PTLDs have been published, rituximab in combination with polychemotherapy, including cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisolone (CHOP), has been proven to be effective for CD20-positive PTLDs. Therapeutic options for patients with CD20-negative PTLDs are limited; CD30 could be a novel drug target. Brentuximab vedotin is an anti-CD30 antibody drug conjugate that has shown beneficial effects in CD30-positive lymphomas, and it is currently under further evaluation in phase 2 clinical trials.